FAS and neoplasm: found that approximately 50% of ENKTL patients harbored FAS gene deletions or mutations, which impaired the formation of the death-inducing signaling complex, leading to inactivation of the FAS signaling pathway and enabling tumor cells to evade apoptosis (42, 43).